Suppr超能文献

探讨脉管侵犯标志物在甲状腺乳头状癌中的临床应用价值:文献综述。

Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review.

机构信息

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.

出版信息

Front Endocrinol (Lausanne). 2023 Nov 27;14:1261860. doi: 10.3389/fendo.2023.1261860. eCollection 2023.

Abstract

Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, and angioinvasion, the invasion of blood vessels by cancer cells, is a crucial pathological feature associated with disease progression and poor prognosis. Thus, a comprehensive search of scientific databases was conducted to identify relevant studies investigating angioinvasion markers in PTC. The selected studies were reviewed and analyzed to assess the clinical significance and potential utility of these markers in predicting angioinvasion and guiding treatment decisions. Numerous studies have investigated various markers associated with angioinvasion in PTC, including oxidative stress, vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and other angiogenic factors. The results indicate that increased expression of these markers is correlated with the presence and extent of angioinvasion in PTC. Moreover, some studies suggest that these markers can serve as prognostic indicators and guide therapeutic strategies, such as selecting patients for more aggressive treatment approaches or targeted therapies. The findings from the reviewed literature highlight the potential clinical utility of angioinvasion markers in PTC. The identification and validation of reliable markers can aid in assessing the risk of angioinvasion, predicting disease progression, and optimizing treatment decisions for patients with PTC. However, further research and validation on larger patient cohorts are necessary to establish the robustness and generalizability of these markers in clinical practice.

摘要

甲状腺乳头状癌 (PTC) 是最常见的甲状腺癌类型,血管侵犯,即癌细胞侵犯血管,是与疾病进展和预后不良相关的关键病理特征。因此,我们对科学数据库进行了全面检索,以确定研究 PTC 血管侵犯标志物的相关研究。对选定的研究进行了回顾和分析,以评估这些标志物在预测血管侵犯和指导治疗决策方面的临床意义和潜在效用。许多研究已经研究了与 PTC 血管侵犯相关的各种标志物,包括氧化应激、血管内皮生长因子 (VEGF)、基质金属蛋白酶 (MMPs) 和其他血管生成因子。结果表明,这些标志物的表达增加与 PTC 中血管侵犯的存在和程度相关。此外,一些研究表明,这些标志物可用作预后指标,并指导治疗策略,例如选择更积极的治疗方法或靶向治疗的患者。综述文献的结果强调了血管侵犯标志物在 PTC 中的潜在临床应用。识别和验证可靠的标志物有助于评估血管侵犯的风险、预测疾病进展,并为 PTC 患者优化治疗决策。然而,需要对更大的患者队列进行进一步的研究和验证,以确定这些标志物在临床实践中的稳健性和通用性。

相似文献

1
Exploring the clinical utility of angioinvasion markers in papillary thyroid cancer: a literature review.
Front Endocrinol (Lausanne). 2023 Nov 27;14:1261860. doi: 10.3389/fendo.2023.1261860. eCollection 2023.
2
Enhancing Angioinvasion Assessment in Papillary Thyroid Cancer Via a Biomarker Panel Involving TAC, 8-OHdG, and Sortilin.
J Clin Endocrinol Metab. 2024 Jun 17;109(7):1866-1872. doi: 10.1210/clinem/dgae007.
5
Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma.
Thyroid. 2009 Nov;19(11):1233-7. doi: 10.1089/thy.2008.0179.
6
Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers.
Clin Transl Oncol. 2022 Dec;24(12):2366-2378. doi: 10.1007/s12094-022-02891-y. Epub 2022 Jul 28.
7
Papillary thyroid carcinoma with pleomorphic tumor giant cells in a pregnant woman - a case report.
BMC Endocr Disord. 2018 Jul 5;18(1):46. doi: 10.1186/s12902-018-0275-x.
10
Significance of multifocality in papillary thyroid carcinoma.
Eur J Surg Oncol. 2020 Oct;46(10 Pt A):1820-1828. doi: 10.1016/j.ejso.2020.06.015. Epub 2020 Jun 19.

引用本文的文献

本文引用的文献

2
Guidance to best tools and practices for systematic reviews.
Syst Rev. 2023 Jun 8;12(1):96. doi: 10.1186/s13643-023-02255-9.
4
Role of Matrix Metalloproteinases and Their Inhibitors in Locally Invasive Papillary Thyroid Cancer.
Biomedicines. 2022 Dec 8;10(12):3178. doi: 10.3390/biomedicines10123178.
6
Oxidative Stress Correlates with More Aggressive Features in Thyroid Cancer.
Cancers (Basel). 2022 Nov 28;14(23):5857. doi: 10.3390/cancers14235857.
7
The Incidence Trend of Papillary Thyroid Carcinoma in the United States During 2003-2017.
Cancer Control. 2022 Jan-Dec;29:10732748221135447. doi: 10.1177/10732748221135447.
8
Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Front Endocrinol (Lausanne). 2022 Aug 11;13:960682. doi: 10.3389/fendo.2022.960682. eCollection 2022.
9
Safety and efficacy of ultrasound-guided thermal ablation in treating T1aN0M0 and T1bN0M0 papillary thyroid carcinoma: A meta-analysis.
Front Endocrinol (Lausanne). 2022 Jul 27;13:952113. doi: 10.3389/fendo.2022.952113. eCollection 2022.
10
Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies.
J Clin Endocrinol Metab. 2022 Sep 28;107(10):2945-2952. doi: 10.1210/clinem/dgac468.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验